New BTK inhibitor helps with therapy-refractory chronic spontaneous urticaria – Deutsches Ärzteblatt

Barcelona – The Bruton's tyrosine kinase (BTK) inhibitor rilzabrutinib effectively reduces disease activity in patients with chronic spontaneous urticaria (CSU) who have not responded adequately to H1 antihistamines, while maintaining an acceptable tolerability profile. These results come from a study published in JAMA Dermatology...